<DOC>
	<DOCNO>NCT01569048</DOCNO>
	<brief_summary>Various maneuver commonly use achieve ideal operative field necessary successful endoscopic sinus surgery ( ESS ) . Dexmedetomidine , potent alpha2 adrenoceptor agonist dose-dependently reduces arterial blood pressure heart rate , decrease hemodynamic catecholamine response . And dexmedetomidine effect peripheral vasoconstriction thus thus theologically appropriate reduce bleed intranasal operation . The aim study compare effect dexmedetomidine , alpha2-adrenoreceptor agonist , intraoperative bleeding , propofol requirement postoperative profile remifentanil , ultrashort-acting opioid .</brief_summary>
	<brief_title>Randomized Controlled Trial Evaluate Dexmedetomidine Effect Operative Visibility Patients Undergoing Endoscopic Sinus Surgery</brief_title>
	<detailed_description />
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<mesh_term>Remifentanil</mesh_term>
	<criteria>ASA ⅠⅡ Aged 20 70 year General anesthesia endoscopic sinus surgery Body mass index &gt; 30 Congestive heart failure , Sinus Bradycardia ( &lt; 50 BPM ) , Uncontrolled hypertension , Coagulopathy Drug addiction Pregnancy Allergic fungal infection</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>